Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Alzheimer's Research and Therapy Année : 2021

Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model

Marine Tournissac
  • Fonction : Auteur
Tra-My Vu
  • Fonction : Auteur
Nika Vrabic
  • Fonction : Auteur
Clara Hozer
  • Fonction : Auteur
Cyntia Tremblay
  • Fonction : Auteur
Koralie Mélançon
  • Fonction : Auteur
Emmanuel Planel
  • Fonction : Auteur
Fabien Pifferi
Frédéric Calon
  • Fonction : Auteur
  • PersonId : 1138987

Résumé

Background: Old age, the most important risk factor for Alzheimer's disease (AD), is associated with thermoregulatory deficits. Brown adipose tissue (BAT) is the main thermogenic driver in mammals and its stimulation, through β3 adrenergic receptor (β3AR) agonists or cold acclimation, counteracts metabolic deficits in rodents and humans. Studies in animal models show that AD neuropathology leads to thermoregulatory deficits, and cold-induced tau hyperphosphorylation is prevented by BAT stimulation through cold acclimation. Since metabolic disorders and AD share strong pathogenic links, we hypothesized that BAT stimulation through a β3AR agonist could exert benefits in AD as well. Methods: CL-316,243, a specific β3AR agonist, was administered to the triple transgenic mouse model of AD (3xTg-AD) and non-transgenic controls from 15 to 16 months of age at a dose of 1 mg/kg/day i.p. Results: Here, we show that β3AR agonist administration decreased body weight and improved peripheral glucose metabolism and BAT thermogenesis in both non-transgenic and 3xTg-AD mice. One-month treatment with a β3AR agonist increased recognition index by 19% in 16-month-old 3xTg-AD mice compared to pre-treatment (14-monthold). Locomotion, anxiety, and tau pathology were not modified. Finally, insoluble Aβ42/Aβ40 ratio was decreased by 27% in the hippocampus of CL-316,243-injected 3xTg-AD mice. Conclusions: Overall, our results indicate that β3AR stimulation reverses memory deficits and shifts downward the insoluble Aβ42/Aβ40 ratio in 16-month-old 3xTg-AD mice. As β3AR agonists are being clinically developed for metabolic disorders, repurposing them in AD could be a valuable therapeutic strategy.
Fichier principal
Vignette du fichier
TOURNISSAC_2021_Article_842.pdf (2.25 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03432160 , version 1 (17-11-2021)

Identifiants

Citer

Marine Tournissac, Tra-My Vu, Nika Vrabic, Clara Hozer, Cyntia Tremblay, et al.. Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model. Alzheimer's Research and Therapy, 2021, 13, ⟨10.1186/s13195-021-00842-3⟩. ⟨hal-03432160⟩

Collections

MNHN CNRS
30 Consultations
36 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More